Slingshot members are tracking this event:

Phase 1/2 presentation of Jazz Pharma's (JAZZ) CPX-351 in Acute myeloid leukemia expected at ASCO May 31, 2019, 3:45 p.m. CT

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
JAZZ Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cpx-351, Asco 2019, Acute Myeloid Leukemia, Aml